Solan Headlines

DelveInsight’s, “Cirrhosis Pipeline Insight, 2023,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Cirrhosis pipeline landscape. It covers the Cirrhosis pipeline drug profiles, including Cirrhosis clinical trials and nonclinical stage products. It also covers the Cirrhosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

In the Cirrhosis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Cirrhosis clinical trials studies, Cirrhosis NDA approvals (if any), and product development activities comprising the technology, Cirrhosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Key takeaways from the Cirrhosis Pipeline Report

• DelveInsight’s Cirrhosis Pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Cirrhosis treatment.

• The leading Cirrhosis Companies includes GWOXI Stem Cell Applied Technology, Lipocine, Galectin Therapeutics, Pharmicell Co., Ltd., BioVie, Ocera Therapeutics, Gilead Sciences, Chia Tai Tianqing Pharmaceutical Group, Zydus Cadila, Novartis Pharmaceuticals, Genfit, PRISM Pharma Co, Bristol-Myers Squibb, COUR Pharmaceutical Development Company, Inc., HighTide Biopharma, Gannex Pharma Co., Ltd., and others.

• Promising Cirrhosis Pipeline Therapies includes NGM282, IDN-6556, KB174, INT-747, Obeticholic Acid (OCA), and others.

• The Cirrhosis companies and academics are working to assess challenges and seek opportunities that could influence Cirrhosis R&D. The Cirrhosis pipeline therapies under development are focused on novel approaches to treat/improve Cirrhosis.

To explore more information on the latest breakthroughs in the Cirrhosis Pipeline treatment landscape of the report, click here @ Cirrhosis Pipeline Outlook

Cirrhosis Overview

Cirrhosis is scarring (fibrosis) of the liver caused by long-term liver damage. The scar tissue prevents the liver working properly. Cirrhosis is sometimes called end-stage liver disease because it happens after other stages of damage from conditions that affect the liver, such as hepatitis. There are, however, ways to prevent cirrhosis, because the diseases that most commonly lead to it progress slowly, and measures are available to prevent and treat them. Moreover, most cases of hepatocellular carcinoma (HCC) arise in a cirrhotic liver, so cirrhosis prevention is, in fact, also HCC prevention.

Latest Developmental Activities in the Cirrhosis Treatment Landscape

• GXHPC1 therapy preparation contains adipose-derived mesenchymal stem cells (AD-MSCs) and was developed for the treatment of liver cirrhosis. The animal studies suggested that treatment of a diseased liver via GXHPC1 transplantation can abrogate liver fibrosis and facilitate recovery of liver function. Currently, the drug is in Phase II stage of clinical trial evaluation for the treatment of Liver Cirrhosis.

• Belapectin (GR-MD-02) is a proprietary galactoarabino-rhamnogalacturonan polysaccharide polymer comprising galacturonic acid, galactose, arabinose, rhamnose and smaller amounts of other sugars. Structural studies have shown that belapectin binds to galectin-1 and galectin-3, with greater binding affinity to galectin-3. Belapectin targets extracellular galectins. Currently, the drug is in Phase II/III stage of clinical trial evaluation for the treatment of Cirrhosis.

For further information, refer to the detailed Cirrhosis Unmet Needs, Cirrhosis Market Drivers, and Cirrhosis Market Barriers, click here for Cirrhosis Ongoing Clinical Trial Analysis

Cirrhosis Emerging Drugs Profile

• GXHPC 1: GWOXI Stem Cell Applied Technology

GXHPC1 therapy preparation contains adipose-derived mesenchymal stem cells (AD-MSCs) and was developed for the treatment of liver cirrhosis. The animal studies suggested that treatment of a diseased liver via GXHPC1 transplantation can abrogate liver fibrosis and facilitate recovery of liver function. Currently, the drug is in Phase II stage of clinical trial evaluation for the treatment of Liver Cirrhosis.

• LPCN 1148: Lipocine

LPCS 1148 is an oral prodrug of bioidentical testosterone being developed for the management of symptoms associated with cirrhosis. Currently, the drug is in Phase II of clinical trial evaluation for the treatment of cirrhosis.

• Belapectin: Galectin Therapeutics

Belapectin (GR-MD-02) is a proprietary galactoarabino-rhamnogalacturonan polysaccharide polymer comprising galacturonic acid, galactose, arabinose, rhamnose and smaller amounts of other sugars. Structural studies have shown that belapectin binds to galectin-1 and galectin-3, with greater binding affinity to galectin-3. Belapectin targets extracellular galectins. Currently, the drug is in Phase II/III stage of clinical trial evaluation for the treatment of Cirrhosis.

Cirrhosis Pipeline Therapeutics Assessment

There are approx. 50+ key companies which are developing the therapies for Cirrhosis. The companies which have their Cirrhosis drug candidates in the most advanced stage, i.e. phase II/III include, Galectin Therapeutics.

Cirrhosis Pipeline: Phases

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Request a sample and discover the recent advances in Cirrhosis Ongoing Clinical Trial Analysis and Medications, click here @ Cirrhosis Treatment Landscape

Scope of the Cirrhosis Pipeline Report

• Coverage- Global

• Cirrhosis Companies- GWOXI Stem Cell Applied Technology, Lipocine, Galectin Therapeutics, Pharmicell Co., Ltd., BioVie, Ocera Therapeutics, Gilead Sciences, Chia Tai Tianqing Pharmaceutical Group, Zydus Cadila, Novartis Pharmaceuticals, Genfit, PRISM Pharma Co, Bristol-Myers Squibb, COUR Pharmaceutical Development Company, Inc., HighTide Biopharma, Gannex Pharma Co., Ltd., and others.

• Cirrhosis Pipeline Therapies- NGM282, IDN-6556, KB174, INT-747, Obeticholic Acid (OCA), and others.

• Cirrhosis Pipeline Segmentation: Product Type, Molecule Type, Route of Administration, Mechanism of Action

Dive deep into rich insights for drugs for Cirrhosis Market Drivers and Cirrhosis Market Barriers, click here @ Cirrhosis Unmet Needs and Analyst Views

Table of Content

1. Introduction
2. Executive Summary
3. Cirrhosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Cirrhosis– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase II/III)
8. Belapectin: Galectin Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. GXHPC 1: GWOXI Stem Cell Applied Technology
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug Name: Company Name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Cirrhosis Key Companies
21. Cirrhosis Key Products
22. Cirrhosis- Unmet Needs
23. Cirrhosis- Market Drivers and Barriers
24. Cirrhosis- Future Perspectives and Conclusion
25. Cirrhosis Analyst Views
26. Cirrhosis Key Companies
27. Appendix

Got Queries? Find out the related information on Cirrhosis Mergers and acquisitions, Cirrhosis Licensing Activities @ Cirrhosis Emerging Drugs, and Recent Trends

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services